The pharma industry's (and the media's) interest in Ebola has begun to wane as more affected African countries secure disease-free status from the World Health Organization, but another tropical condition has started to capture headlines – Zika virus (ZIKV), a mosquito transferred disease reportedly responsible for approximately 4,000 child birth defects since Oct. 2015.
The pharma industry's (and the media's) interest in Ebola has begun to wane as more affected African countries secure disease-free status from the World Health Organization, but another tropical condition has started to capture headlines – Zika virus (ZIKV), a mosquito transferred disease reportedly responsible for approximately 4,000 child birth defects since Oct. 2015.
This time the focus is on Brazil, the location for the 2016 Olympic Games, where an outbreak of ZIKV is...
A new muscle-building front is opening in the fight against obesity, with Lilly among the leaders. But it plans to remain tight-lipped on upcoming Phase II data for its myostatin inhibitor in combination with Novo’s Wegovy for fear of playing into the hands of its rival.
The Mereo-partnered drug is in pivotal development for osteogenesis imperfecta. Ultragenyx also recently reported positive Phase III data for a rare disease gene therapy.
The company sees a $5bn opportunity to treat children with achondroplasia and the less severe growth disorder variant, hypochondroplasia.
Phase I/II data for its ADC candidates in myotonic dystrophy type 1 and Duchenne muscular dystrophy indicate potential for biomarker-based accelerated approval in both diseases, Dyne asserts.
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
